Inteum Company
Links
seedsprint
Visible Legacy
RSS
News & Resources
Inteum Company News
Inteum Library
Subscribe
Search Results - cell+therapy
59
Results
Sort By:
Published Date
Updated Date
Title
ID
Descending
Ascending
Anticancer IgG Against Multiple Epitopes on Live Tumors Upon Disruption of ‘Self’ Signaling by CD47
A method to combine two or three monoclonal antibodies (mABs) into one treatment to successfully bind to multiple cancer cell surface epitopes and promote targeted degradation by phagocytosis. Problem: Phagocytosis of ‘self’ cells is generally inhibited by a key macrophage checkpoint interaction between SIRPα on the macrophage and...
Published: 2/27/2025
|
Inventor(s):
Dennis Discher
,
Jason Andrechak
,
Lawrence Dooling
Keywords(s):
Antibody
,
Bioengineering
,
Cell Therapy
,
Drug Target
,
Immunology
,
Immunoncology
,
Immunotherapy
,
Oncology
,
Platform Technology
Category(s):
Technology Classifications > Therapeutics
T-Cell-Activating Lipid Nanoparticles for Rapid Engineering of CAR T Cells
A method to streamline the process of generating chimeric antigen receptor (CAR) T cells for therapeutic applications. Problem: CAR T
cell therapy
has demonstrated clinical success in treating various forms of cancer. With more CAR T cell therapies projected to gain regulatory approval, manufacturing becomes increasingly important in the face of this...
Published: 12/20/2024
|
Inventor(s):
Ann Metzloff
,
Margaret Billingsley
,
Michael Mitchell
Keywords(s):
Bioengineering
,
Cell Therapy
,
Drug Delivery
,
Immunoncology
,
Immunotherapy
,
Oncology
,
Platform Technology
Category(s):
Technology Classifications > Therapeutics
Method to Alleviate Side Effects of CAR T Cell Immunotherapies
CAR-T cells are PEGylated to block the interactions with monocytes and macrophages to reduce the side effects of CAR-T cell therapies (cytokine release syndrome and neurotoxicity). Problem: CAR-T cell therapies lead to many adverse side effects such as cytokine release syndrome (CRS) and neurotoxicity. It has been shown that 20-70% of patients receiving...
Published: 12/20/2024
|
Inventor(s):
Michael Mitchell
,
Ningqiang Gong
Keywords(s):
Bioengineering
,
Cell Therapy
,
Immunology
,
Immunoncology
,
Immunotherapy
,
Oncology
Category(s):
Technology Classifications > Chemical Processes and Synthesis
,
Technology Classifications > Therapeutics
Safe and Potent mRNA Lipid Nanoparticles (LNPs) for Ex-Vivo Engineering of Immunosuppressive T cells in Autoimmunity Therapies.
Using mRNA-LNPs to deliver forkhead box protein 3 (Foxp3) to CD4+ T cells to engineer Foxp3-positive T (FP3T) cells with immunosuppressive properties. Problem: Autoimmune disorders (e.g., type 1 diabetes, multiple sclerosis, and myasthenia gravis) are mediated by self-reactive lymphocyte (B or T cells) expansion. Available suppressive medications like...
Published: 10/1/2024
|
Inventor(s):
Michael Mitchell
,
Ajay Thatte
,
Alvin Mukalel
Keywords(s):
Bioengineering
,
Cell Therapy
,
Drug Delivery
,
Immunology
,
Immunotherapy
,
Platform Technology
Category(s):
Technology Classifications > Chemical Processes and Synthesis
,
Technology Classifications > Therapeutics
Tumor Suppression by Retinoic Acid Pathway Inhibition
Targeting retinoic acid (RA) synthesizing enzymes or RA receptors with small molecules boosts the immune system towards a tumor rejection response Problem: Hepatocellular carcinoma (HCC) is the most common liver cancer globally. In the US alone, 33 000 patients are diagnosed yearly, 27 000 of which will die. Once metastasized, HCC shows...
Published: 6/21/2024
|
Inventor(s):
Malay Haldar
,
Ganesha Rai Bantukallu
Keywords(s):
Cell Therapy
,
Drug Target
,
Immunology
,
Immunoncology
,
Oncology
,
Small Molecule
Category(s):
Technology Classifications > Therapeutics
Optimizing the Engineering of CAR-T Cells
Application A method for selecting distinct T cell populations in order to generate more effective CAR-T cells. Key Benefits The proposed invention focuses on selecting the optimal “starting material” for the engineering CAR-T cells. This selection method can be utilized for the development of any and all CAR-T therapies, not limited...
Published: 2/13/2025
|
Inventor(s):
Byron Au-Yeung
Keywords(s):
Cell Therapy
,
Oncology Treatments
,
Production Methods
Category(s):
TechPub Algolia > Research Tools
,
TechPub Algolia > Therapeutics
Advancing Lymphatic Endothelial Cell Generation from iPSCs
Application The developed protocol offers a reproducible and scalable method for generating lymphatic endothelial cells (LECs) from induced pluripotent stem cells (iPSCs), addressing critical challenges in the field of lymphatic-related therapies. Key Benefits Reproducible and scalable protocol for generating LECs from iPSCs. Utilizes specific...
Published: 2/13/2025
|
Inventor(s):
Katherine Hekman
,
Katherine Owsiany
Keywords(s):
Cell Therapy
,
Production Methods
Category(s):
TechPub Algolia > Therapeutics
,
TechPub Algolia > Drug Discovery
Treating Prostate Cancer with Novel Sugar-Antigen-Targeting CAR-T Cells
Problem: While the 5-year relative survival rate for patients with local or regional prostate cancer is nearly 100%, the 5-year relative survival rate drops to 32% for patients with metastatic or advanced disease. These patients may initially respond to available therapies, but most patients will develop therapy resistance and succumb to disease. Solution: A...
Published: 6/20/2024
|
Inventor(s):
Mark Greene
,
Michael Milone
Keywords(s):
Cell Therapy
,
Oncology
Category(s):
Technology Classifications > Therapeutics
Induced Pluripotent Stem Cells Derived from Patients with CEP290-associated Ciliopathies and Unaffected Family Members
Abstract: Approximately one-third of non-syndromic retinal dystrophies involve a defect in a ciliary protein. Non-syndromic retinal ciliopathies include retinitis pigmentosa, cone dystrophy, cone-rod dystrophy, macular dystrophy, and Leber-congenital amaurosis (LCA). Many CEP290-LCA patients also exhibit auditory and olfactory defects. Induced pluripotent...
Published: 12/6/2024
|
Inventor(s):
Anand Swaroop
,
Hiroko Shimada-Ishii
,
Yu Holly Chen
,
Milton English
Keywords(s):
Anosmia
,
Cell therapy
,
Ciliopathies
,
Congenital Blindness
,
Drug Development
,
GENE THERAPY
,
hearing loss
,
iPS
,
National Eye Institute
,
NEI
,
Pluripotent Stem Cells
,
Primary Cilia
,
Retina
,
Retinal degeneration
,
Swaroop
,
VISION
Category(s):
Application > Research Materials
,
Collaboration Sought > Licensing
,
Collaboration Sought > Collaboration
,
TherapeuticArea > Ear, Nose, & Throat
,
TherapeuticArea > Ophthalmology
3D Vascularized Human Ocular Tissue for
Cell Therapy
and Drug Discovery
Abstract: Degeneration of retinal tissues occurs in many ocular disorders resulting in the loss of vision. Dysfunction and/or loss of Retinal Pigment Epithelium Cells (RPE) and disruption of the associated blood retinal barrier (BRB) tissue structures are linked with many ocular diseases and conditions including: age-related macular degeneration (AMD),...
Published: 12/6/2024
|
Inventor(s):
Kapil Bharti
,
Min Jae Song
,
Russell Quinn
Keywords(s):
3D bio-printing
,
Bharti
,
Blood Retinal Barrier Disorder
,
BRB
,
Cell therapy
,
in Vitro Human Blood Retinal Barrier Model
,
Ocular
cell therapy
scaffold
,
Retinal disorder
,
Retinal Pigment Epithelium Cells
Category(s):
Collaboration Sought > Collaboration
,
Collaboration Sought > Licensing
,
Application > Therapeutics
,
TherapeuticArea > Ear, Nose, & Throat
,
TherapeuticArea > Ophthalmology
1
2
3
4
5
6